http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 11:53:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++Arcus+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Jaen+Juan+C./26772899.html si-local-file:///var/storage/secattach/20260715/26772899.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Arcus+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Jaen+Juan+C./26772899.html Wed, 15 Jul 2026 11:53:00 -0400 O.29486884 RCUS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Arcus+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Jaen+Juan+C./26772899.html si-local-file:///var/storage/secattach/20260715/26772899.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Arcus+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Jaen+Juan+C./26772899.html Wed, 15 Jul 2026 11:53:00 -0400 O.29486884 RCUS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcus+Biosciences%2C+Inc.+++For%3A+Jul+09++Filed+by%3A+Jaen+Juan+C./26763354.html si-local-file:///var/storage/secattach/20260713/26763354.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcus+Biosciences%2C+Inc.+++For%3A+Jul+09++Filed+by%3A+Jaen+Juan+C./26763354.html Mon, 13 Jul 2026 17:37:00 -0400 O.29486884 RCUS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcus+Biosciences%2C+Inc.+++For%3A+Jul+09++Filed+by%3A+Jaen+Juan+C./26763354.html si-local-file:///var/storage/secattach/20260713/26763354.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcus+Biosciences%2C+Inc.+++For%3A+Jul+09++Filed+by%3A+Jaen+Juan+C./26763354.html Mon, 13 Jul 2026 17:37:00 -0400 O.29486884 RCUS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Arcus+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Jaen+Juan+C./26754101.html si-local-file:///var/storage/secattach/20260709/26754101.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Arcus+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Jaen+Juan+C./26754101.html Thu, 09 Jul 2026 18:31:00 -0400 O.29486884 RCUS http://www.streetinsider.com/SEC+Filings/Form++144++++++++Arcus+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Jaen+Juan+C./26754101.html si-local-file:///var/storage/secattach/20260709/26754101.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Arcus+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Jaen+Juan+C./26754101.html Thu, 09 Jul 2026 18:31:00 -0400 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+New+Employment+Inducement+Grants/26753643.html <p> HAYWARD, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify">Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employee options to purchase a total of 16,060 shares of the Company’s common stock at an exercise price per share of $30.26, which was the closing price on July 8, 2026, and restricted stock units to acquire a total of 8,080 shares of the Company’s common stock. The equity awards were granted http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+New+Employment+Inducement+Grants/26753643.html Thu, 09 Jul 2026 16:35:00 -0400 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+New+Employment+Inducement+Grants/26753643.html <p> HAYWARD, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify">Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employee options to purchase a total of 16,060 shares of the Company’s common stock at an exercise price per share of $30.26, which was the closing price on July 8, 2026, and restricted stock units to acquire a total of 8,080 shares of the Company’s common stock. The equity awards were granted http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+New+Employment+Inducement+Grants/26753643.html Thu, 09 Jul 2026 16:35:00 -0400 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+New+Employment+Inducement+Grants/26753643.html <p> HAYWARD, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify">Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employee options to purchase a total of 16,060 shares of the Company’s common stock at an exercise price per share of $30.26, which was the closing price on July 8, 2026, and restricted stock units to acquire a total of 8,080 shares of the Company’s common stock. The equity awards were granted http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+New+Employment+Inducement+Grants/26753643.html Thu, 09 Jul 2026 16:35:00 -0400 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+New+Employment+Inducement+Grants/26753643.html <p> HAYWARD, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify">Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employee options to purchase a total of 16,060 shares of the Company’s common stock at an exercise price per share of $30.26, which was the closing price on July 8, 2026, and restricted stock units to acquire a total of 8,080 shares of the Company’s common stock. The equity awards were granted http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+New+Employment+Inducement+Grants/26753643.html Thu, 09 Jul 2026 16:35:00 -0400 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+kidney+cancer+drug+data+published+in+Nature+journal/26718637.html <p>Arcus Biosciences (NYSE: RCUS) announced the publication of research in <em>Nature</em> from its ARC-20 study evaluating casdatifan, an investigational HIF-2a inhibitor, as a monotherapy in patients with metastatic clear cell renal cell carcinoma (ccRCC).</p><p>The study, according to the company, is the first to examine the relationship between HIF-2a inhibitor-associated changes in circulating serum erythropoietin (EPO), tumor biology, and clinical outcomes. Researchers found that deeper suppression of serum EPO correlated with higher response rates and longer progression-free survival (PFS).</p><p>In a pooled analysis of four monotherapy cohorts (n=121), the confirmed objective response rate was 31% and median PFS was 12.2 months. More http://www.streetinsider.com/Corporate+News/Arcus+kidney+cancer+drug+data+published+in+Nature+journal/26718637.html Wed, 01 Jul 2026 11:00:38 -0400 RCUS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Press+Releases/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Business+Wire/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Business+Wire/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Business+Wire/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html <ul class="bwlistdisc"> <li> This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology </li> </ul><ul class="bwlistdisc"> <li> HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS) </li> </ul><ul class="bwlistdisc"> <li> A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens </li> </ul> <p> HAYWARD, Calif.--(BUSINESS http://www.streetinsider.com/Business+Wire/New+Research+Published+in+Nature+Links+Clinical+Activity+with+HIF%E2%80%912a+Biology+in+Advanced+Kidney+Cancer+Patients+Treated+with+Casdatifan/26718603.html Wed, 01 Jul 2026 11:00:00 -0400 A.20922990 A.22847412 A.35954321 A.50210832 O.00048977 O.00199090 O.03960636 O.20737027 O.29486884 RCUS